ProPhase Labs to Present at the 2024 ThinkEquity Conference
ProPhase Labs (NASDAQ: PRPH), a next generation biotech, genomics, and diagnostics company, has announced its participation in The ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York. Ted Karkus, CEO and Chairman of the Board of Directors, will present at 1PM ET on October 30th.
The conference is known for featuring numerous company presentations, attracting hundreds of attendees, and facilitating one-on-one meetings between companies and investors. ProPhase's presentation will be live-streamed, and interested investors can register to attend and schedule one-on-one meetings throughout the day.
This event provides ProPhase Labs with a valuable opportunity to connect with potential investors and showcase their latest developments in the biotech, genomics, and diagnostics sectors.
ProPhase Labs (NASDAQ: PRPH), un'azienda biotech, genomica e diagnostica di nuova generazione, ha annunciato la sua partecipazione a The ThinkEquity Conference il 30 ottobre 2024, presso il Mandarin Oriental Hotel di New York. Ted Karkus, CEO e Presidente del Consiglio di Amministrazione, presenterà alle 1PM ET del 30 ottobre.
La conferenza è nota per le numerose presentazioni aziendali, attirando centinaia di partecipanti e facilitando incontri one-to-one tra aziende e investitori. La presentazione di ProPhase sarà trasmessa in diretta, e gli investitori interessati possono registrarsi per partecipare e pianificare incontri individuali durante la giornata.
Questo evento offre a ProPhase Labs un'opportunità preziosa per connettersi con potenziali investitori e mostrare i suoi ultimi sviluppi nei settori biotech, genomica e diagnostica.
ProPhase Labs (NASDAQ: PRPH), una empresa de biotecnología, genómica y diagnóstico de nueva generación, ha anunciado su participación en The ThinkEquity Conference el 30 de octubre de 2024, en el Hotel Mandarin Oriental de Nueva York. Ted Karkus, CEO y Presidente de la Junta Directiva, presentará a la 1PM ET del 30 de octubre.
La conferencia es conocida por incluir numerosas presentaciones de empresas, atraer a cientos de asistentes y facilitar reuniones uno a uno entre las empresas y los inversores. La presentación de ProPhase será transmitida en vivo, y los inversores interesados pueden registrarse para asistir y programar reuniones individuales durante el día.
Este evento proporciona a ProPhase Labs una valiosa oportunidad de conectar con posibles inversores y mostrar sus últimos desarrollos en los sectores de biotecnología, genómica y diagnóstico.
프로페이즈 랩스 (NASDAQ: PRPH)는 차세대 생명공학, 유전체학 및 진단 회사로서 ThinkEquity 회의에 참여할 예정이라고 발표했습니다. 이 회의는 2024년 10월 30일, 뉴욕의 만다린 오리엔탈 호텔에서 열릴 예정입니다. 테드 카카스 CEO이자 이사회 의장은 10월 30일 오후 1시 ET에 발표할 예정입니다.
이 회의는 많은 기업 발표로 알려져 있으며, 수백 명의 참석자를 끌어모으고 기업과 투자자 간의 일대일 미팅을 촉진합니다. 프로페이즈의 발표는 실시간으로 스트리밍될 것이며, 관심 있는 투자자는 참석 등록을 하고 하루 동안 개별 미팅을 일정에 추가할 수 있습니다.
이 행사로 프로페이즈 랩스는 잠재 투자자와 연결하고 생명공학, 유전체학 및 진단 분야에서의 최신 개발 사항을 보여줄 수 있는 귀중한 기회를 제공합니다.
ProPhase Labs (NASDAQ: PRPH), une entreprise biotechnologique, génomique et diagnostique de nouvelle génération, a annoncé sa participation à The ThinkEquity Conference le 30 octobre 2024, à l'hôtel Mandarin Oriental à New York. Ted Karkus, PDG et Président du Conseil d'Administration, présentera à 13h ET le 30 octobre.
La conférence est connue pour présenter de nombreuses entreprises, attirer des centaines de participants et faciliter des rencontres individuelles entre entreprises et investisseurs. La présentation de ProPhase sera diffusée en direct, et les investisseurs intéressés peuvent s'inscrire pour assister à l'événement et planifier des réunions individuelles tout au long de la journée.
Cet événement offre à ProPhase Labs une occasion précieuse de se connecter avec des investisseurs potentiels et de présenter ses derniers développements dans les secteurs de la biotechnologie, de la génomique et du diagnostic.
ProPhase Labs (NASDAQ: PRPH), ein Unternehmen der nächsten Generation in der Biotechnologie, Genomik und Diagnostik, hat seine Teilnahme an The ThinkEquity Conference am 30. Oktober 2024 im Mandarin Oriental Hotel in New York angekündigt. Ted Karkus, CEO und Vorsitzender des Vorstands, wird am 30. Oktober um 13 Uhr ET präsentieren.
Die Konferenz ist bekannt für zahlreiche Unternehmenspräsentationen, die Hunderte von Teilnehmern anziehen und persönliche Gespräche zwischen Unternehmen und Investoren ermöglichen. Die Präsentation von ProPhase wird live gestreamt, und interessierte Investoren können sich anmelden, um an der Veranstaltung teilzunehmen und während des Tages Einzelgespräche zu planen.
Diese Veranstaltung bietet ProPhase Labs eine wertvolle Gelegenheit, mit potenziellen Investoren in Kontakt zu treten und ihre neuesten Entwicklungen in den Bereichen Biotechnologie, Genomik und Diagnostik zu präsentieren.
- None.
- None.
GARDEN CITY, NY, Oct. 22, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (the “Company” or “ProPhase”), a next generation biotech, genomics, and diagnostics company, today announced that it will be participating in The ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York. Past ThinkEquity conferences have featured over 70 company presentations, 700+ attendees, and 500+ one-on-one meetings, providing a valuable platform for companies and investors to connect.".
Ted Karkus, CEO and Chairman of the Board of Directors, will be presenting at 1PM ET on October 30th. One-on-one investor meetings will be held throughout the day. Interested investors can register to attend and schedule one-on-one meetings here.
The presentation will also be live-streamed at the following link: https://wsw.com/webcast/tep25/prph/1692576
About ProPhase Labs
ProPhase Labs Inc. (Nasdaq: PRPH) (“ProPhase”) is a next-generation biotech, genomics and diagnostics company. Our goal is to create a healthier world with bold action and the power of insight. We’re revolutionizing healthcare with industry-leading Whole Genome Sequencing solutions, while developing potential game changer diagnostics and therapeutics in the fight against cancer. This includes a potentially life-saving cancer test focused on early detection of esophageal cancer and potential breakthrough cancer therapeutics with novel mechanisms of action. Our world-class CLIA labs and cutting-edge diagnostic technology provide wellness solutions for healthcare providers and consumers. We develop, manufacture, and commercialize health and wellness solutions to enable people to live their best lives. We are committed to executional excellence, smart diversification, and a synergistic, omni-channel approach. ProPhase Labs’ valuable subsidiaries, their synergies, and significant growth underscore our multi-billion-dollar potential.
Media Relations and Institutional Investor Contact:
ProPhase Labs, Inc.
267-880-1111
investorrelations@prophaselabs.com
Retail Investor Relations Contact:
Renmark Financial Communications
John Boidman
514-939-3989
Jboidman@renmarkfinancial.com
Source: ProPhase Labs, Inc.
FAQ
When and where is ProPhase Labs (PRPH) presenting at the ThinkEquity Conference?
Who will be presenting for ProPhase Labs (PRPH) at the 2024 ThinkEquity Conference?
How can investors attend or view ProPhase Labs' (PRPH) presentation at the ThinkEquity Conference?
What type of company is ProPhase Labs (PRPH)?
